Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DSGNNASDAQ:ENGNNASDAQ:HOWLNASDAQ:KOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDSGNDesign Therapeutics$3.68-4.9%$3.76$2.60▼$7.77$212.03M1.62182,382 shs48,414 shsENGNenGene$3.28-1.1%$3.77$2.65▼$11.00$166.19M-0.4128,624 shs12,728 shsHOWLWerewolf Therapeutics$1.22-6.5%$1.03$0.60▼$4.18$54.52M0.66441,699 shs221,482 shsKODKodiak Sciences$3.56-4.8%$3.62$1.92▼$11.60$188.00M2.27347,724 shs163,960 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDSGNDesign Therapeutics+0.78%-1.02%+10.26%-19.54%+4.31%ENGNenGene-0.60%-1.19%-4.06%-35.73%-63.22%HOWLWerewolf Therapeutics+6.56%-7.80%+17.12%+12.07%-56.81%KODKodiak Sciences-3.61%-9.88%+6.86%+15.43%+33.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDSGNDesign Therapeutics0.7357 of 5 stars1.01.00.00.03.32.50.6ENGNenGene2.4493 of 5 stars3.53.00.00.01.02.50.6HOWLWerewolf Therapeutics3.7277 of 5 stars3.53.00.00.03.35.00.6KODKodiak Sciences4.3572 of 5 stars3.04.00.04.62.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDSGNDesign Therapeutics 2.00Hold$4.008.70% UpsideENGNenGene 3.00Buy$23.29611.01% UpsideHOWLWerewolf Therapeutics 3.00Buy$8.33585.87% UpsideKODKodiak Sciences 2.00Hold$9.00152.81% UpsideCurrent Analyst Ratings BreakdownLatest HOWL, DSGN, ENGN, and KOD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025HOWLWerewolf TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $6.004/29/2025ENGNenGeneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.003/31/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDSGNDesign TherapeuticsN/AN/AN/AN/A$4.96 per shareN/AENGNenGeneN/AN/AN/AN/A$6.17 per shareN/AHOWLWerewolf Therapeutics$1.14M47.70N/AN/A$3.08 per share0.39KODKodiak SciencesN/AN/AN/AN/A$5.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDSGNDesign Therapeutics-$66.86M-$0.99N/AN/AN/AN/A-18.01%-17.38%8/4/2025 (Estimated)ENGNenGene-$55.14M-$1.52N/AN/AN/AN/A-16.69%-14.27%N/AHOWLWerewolf Therapeutics-$37.37M-$1.67N/AN/AN/A-578.80%-58.83%-38.45%8/14/2025 (Estimated)KODKodiak Sciences-$260.49M-$3.63N/AN/AN/AN/A-84.52%-45.40%8/13/2025 (Estimated)Latest HOWL, DSGN, ENGN, and KOD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/10/2025Q2 2025ENGNenGene-$0.4768-$0.51-$0.0332-$0.51N/AN/A5/14/2025Q1 2025DSGNDesign Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/A5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/8/2025Q1 2025HOWLWerewolf Therapeutics-$0.44-$0.40+$0.04-$0.40$0.30 millionN/A3/27/2025Q4 2024KODKodiak Sciences-$0.90-$0.84+$0.06-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDSGNDesign TherapeuticsN/AN/AN/AN/AN/AENGNenGene$1.5848.27%N/AN/A N/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDSGNDesign TherapeuticsN/A34.6134.61ENGNenGene0.0816.8716.87HOWLWerewolf Therapeutics0.2910.1010.10KODKodiak SciencesN/A8.428.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDSGNDesign Therapeutics56.64%ENGNenGene64.16%HOWLWerewolf Therapeutics64.84%KODKodiak Sciences89.06%Insider OwnershipCompanyInsider OwnershipDSGNDesign Therapeutics31.20%ENGNenGene10.40%HOWLWerewolf Therapeutics23.60%KODKodiak Sciences45.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDSGNDesign Therapeutics4056.77 million38.96 millionOptionableENGNenGene3150.98 million38.16 millionN/AHOWLWerewolf Therapeutics4044.87 million35.16 millionOptionableKODKodiak Sciences9052.76 million28.79 millionOptionableHOWL, DSGN, ENGN, and KOD HeadlinesRecent News About These CompaniesKodiak Sciences Inc. (NASDAQ:KOD) Short Interest UpdateJune 17 at 9:55 AM | marketbeat.comBank of America Corp DE Has $169,000 Stock Holdings in Kodiak Sciences Inc. (NASDAQ:KOD)June 16 at 3:01 AM | marketbeat.comWhy Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?June 13, 2025 | zacks.comTrump’s cuts to fisheries science have industry and conservation groups sounding alarmJune 11, 2025 | kucb.orgAlaska Aerospace, UAF to partner on new space venturesJune 11, 2025 | kodiakdailymirror.comQ2 EPS Estimates for Kodiak Sciences Cut by Zacks ResearchJune 8, 2025 | americanbankingnews.comQ2 EPS Forecast for Kodiak Sciences Reduced by AnalystJune 6, 2025 | marketbeat.comRetinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJune 5, 2025 | theglobeandmail.comKodiak Sciences to Present at 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | prnewswire.comKodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroadsMay 29, 2025 | investing.comKodiak Sciences Q2 EPS Forecast Decreased by HC WainwrightMay 23, 2025 | marketbeat.comPoint72 Asset Management L.P. Buys New Shares in Kodiak Sciences Inc. (NASDAQ:KOD)May 22, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Reduces Position in Kodiak Sciences Inc. (NASDAQ:KOD)May 17, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Invests $902,000 in Kodiak Sciences Inc. (NASDAQ:KOD)May 17, 2025 | marketbeat.comKodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial ResultsMay 15, 2025 | finanznachrichten.deKodiak Sciences Shares Drop After Wider-Than-Expected 1Q LossMay 15, 2025 | marketwatch.comKodiak Q1 Loss Wider Than Expected, Pipeline Development in FocusMay 15, 2025 | zacks.comKodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial ResultsMay 14, 2025 | prnewswire.comWhy Kodiak Sciences Inc.’s (KOD) Stock Is Down 15.35%May 7, 2025 | aaii.comBlackRock, Inc. Reduces Stake in Kodiak Sciences Inc.May 6, 2025 | gurufocus.comMore companies announce ARVO 2025 presentationsMay 2, 2025 | ophthalmologytimes.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOWL, DSGN, ENGN, and KOD Company DescriptionsDesign Therapeutics NASDAQ:DSGN$3.69 -0.18 (-4.60%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.enGene NASDAQ:ENGN$3.29 -0.02 (-0.63%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Werewolf Therapeutics NASDAQ:HOWL$1.20 -0.10 (-7.31%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.Kodiak Sciences NASDAQ:KOD$3.55 -0.19 (-5.05%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside Is CrowdStrike Stock Set to Break Out or Cool Off? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 The Bottom Is in for Powerfleet: An Intelligent Time to Buy AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Why Nebius Group Is One of the Top AI Stocks to Watch Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
